A randomized, double-blind, multi-centre, placebo-controlled, parallel-arm phase 2 trial to assess safety, efficacy and pharmacokinetics of CD11301 0.03% and 0.06% gel in the treatment of Cutaneous T-Cell Lymphoma (CTCL), stages IA, IB and IIA

UCI-17-82
NCT03292406
Cancer - Mycosis Fungoides, Cancer - Non-Hodgkin's Lymphoma
Lauren C Pinter-Brown
Open
Treatment
Placebo, Resiquimod (CD11301)
II
Adult
National

For information about cancer clinical trials at the UCI Health Chao Family Comprehensive Cancer Center, call toll-free 877-UC-STUDY (877-827-8839) or email ucstudy@uci.edu.